More than 85% of myelodysplastic syndrome cases occur in adults 60 and older, with claims-based data placing true incidence in those 65 and up at approximately 75 per 100,000 annually, nearly three times the SEER registry estimate, a sign of significant under-documentation. Overall 5-year survival is approximately 37%, ranging from a median of 3-10 years in lower-risk disease to under 3 years in higher-risk disease. Because MDS is frequently dismissed as ordinary anemia of aging, precise subtype and risk-stratification documentation directly affects both diagnosis and downstream risk adjustment.
AAVBC's Myelodysplastic Syndromes Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering ICD-10 D46 subtype coding and HCC 19/RAF mapping, WHO/ICC 2022 diagnostic criteria, IPSS-R and IPSS-M risk stratification, geriatric risk factors and comorbidity screening, recoding at AML transformation, MEAT documentation standards, and NCCN-aligned treatment and referral pathways. Grounded in NCCN v3.2026 and current CMS coding guidance, this guide supports consistent, individualized clinical decision-making, helping care teams distinguish MDS from reversible causes of cytopenia and document subtype and risk with precision, with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of MDS — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
More than 85% of myelodysplastic syndrome cases occur in adults 60 and older, with claims-based data placing true incidence in those 65 and up at approximately 75 per 100,000 annually, nearly three times the SEER registry estimate, a sign of significant under-documentation. Overall 5-year survival is approximately 37%, ranging from a median of 3-10 years in lower-risk disease to under 3 years in higher-risk disease. Because MDS is frequently dismissed as ordinary anemia of aging, precise subtype and risk-stratification documentation directly affects both diagnosis and downstream risk adjustment.
AAVBC's Myelodysplastic Syndromes Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering ICD-10 D46 subtype coding and HCC 19/RAF mapping, WHO/ICC 2022 diagnostic criteria, IPSS-R and IPSS-M risk stratification, geriatric risk factors and comorbidity screening, recoding at AML transformation, MEAT documentation standards, and NCCN-aligned treatment and referral pathways. Grounded in NCCN v3.2026 and current CMS coding guidance, this guide supports consistent, individualized clinical decision-making, helping care teams distinguish MDS from reversible causes of cytopenia and document subtype and risk with precision, with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of MDS — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
